糖尿病行为干预关键技术研究-基于信息化平台的健康行为模式构建

注册号:

Registration number:

ChiCTR-IOR-15005901 

最近更新日期:

Date of Last Refreshed on:

2015-01-29 20:17:55 

注册时间:

Date of Registration:

2014-04-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

糖尿病行为干预关键技术研究-基于信息化平台的健康行为模式构建

Public title:

Key technology research on behavior intervention for diabetes in China: based on the information platform

注册题目简写:

English Acronym:

研究课题的正式科学名称:

糖尿病行为干预关键技术研究-基于信息化平台的健康行为模式构建

Scientific title:

Key technology research on behavior intervention for diabetes in China: based on the information platform

研究课题代号(代码):

Study subject ID:

20141027

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

漆莉 

研究负责人:

熊鸿燕 

Applicant:

Qi Li 

Study leader:

Xiong Hongyan 

申请注册联系人电话:

Applicant telephone:

+86 13896151696

研究负责人电话:

Study leader's
telephone:

+86 13062332762

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qili19812012@126.com

研究负责人电子邮件:

Study leader's E-mail:

hongyanxiong@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区长江二路8号

研究负责人通讯地址:

重庆市沙坪坝区高滩岩30号

Applicant address:

8 Changjiang Er Road, Yuzhong District, Chongqing, China

Study leader's address:

30 Gaotanyan Street, Shapingba District, Chongqing, China

申请注册联系人邮政编码:

Applicant postcode:

40042

研究负责人邮政编码:

Study leader's postcode:

40042

申请人所在单位:

第三军医大学

Applicant's institution:

Third Military Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

Nil

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

第三军医大学伦理审查委员会

Name of the ethic committee:

Ethical Committee of Research in Third Military Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2014-04-08 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

第三军医大学

Primary sponsor:

Third Military Medical University

研究实施负责(组长)单位地址:

重庆市沙坪坝区高滩岩30号

Primary sponsor's address:

30 Gaotanyan Street, Shapingba District, Chongqing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

重庆市卫生与计划生育委员会

Source(s) of funding:

Health and Family Planning Commission of Chongqing

研究疾病:

糖尿病  

Target disease:

diabetes

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估基于信息化平台的生活方式干预是否有助于降低糖尿病前期患者发生糖尿病的危险性。  

Objectives of Study:

We aim to assess whether information platform-based intervention that encouraged lifestyle modification could reduce the risk of developing diabetes.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

(1)曾诊断为糖尿病患者;(2)不会使用手机短信、微信;(3)由临床医生诊断不适合参加本研究者,如严重的心脑血管疾病、精神心理疾病、癌症等;(4)正在怀孕或哺乳(不包括6周内将结束哺乳的妇女)以及研究期间有怀孕计划的妇女;(5)家庭中另外一个成员是本试验的工作人员;(6)目前或曾经参加了另外的干预研究项目可能会影响干预效果;(7)近半年内服用降糖药、降脂药及减肥药物者;(8)研究者认为受试者存在任何不适合进入本研究的其他情况。

Exclusion criteria:

Subjects were excluded from the study if they
(1) had a history of diabetes mellitus;
(2) unable to use mobile phone;
(3) had major illness,such as cancer, chronic liver or kidney disease;
(4) in pregnant or lactation period or plan to become pregnant during study;
(5) another household member is a staff member in the study;
(6) current or anticipated participation in another intervention research project that would interfere with any of the interventions offered in this trial;
(7) were currently on medication known to alter glucose tolerance; and
(8) conditions not specifically mentioned above may serve as criteria for exclusion at the discretion of the clinic site.

研究实施时间:

Study execute time:

From 2014-12-01 00:00:00 To 2016-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2014-12-01 00:00:00 To 2015-02-28 00:00:00

干预措施:

Interventions:

组别:

1

样本量:

300

Group:

1

Sample size:

干预措施:

强化干预加常规干预

干预措施代码:

Intervention:

Intensive intervention plus conventional intervention

Intervention code:

组别:

2

样本量:

300

Group:

2

Sample size:

干预措施:

常规干预

干预措施代码:

Intervention:

Conventional intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

沙坪坝区疾控中心 

单位级别:

区级卫生机构 

Institution
hospital:

Shapingba Center for Disease Control and Prevention

Level of the institution:

district health agency

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China

Province:

Chongqing

City:

单位(医院):

渝中区疾控中心 

单位级别:

区级卫生机构 

Institution
hospital:

Yuzhong Center for Disease Control and Prevention

Level of the institution:

District health agency

测量指标:

Outcomes:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

Blood glucose level test

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压

指标类型:

主要指标

Outcome:

blood pressure

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

甘油三酯

指标类型:

次要指标

Outcome:

Triglyceride

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总胆固醇

指标类型:

次要指标

Outcome:

total cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

high density lipoprotein cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

低密度脂蛋白胆固醇

指标类型:

次要指标

Outcome:

Low high lipoprotein cholesterol

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

次要指标

Outcome:

Weight

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腰围

指标类型:

次要指标

Outcome:

waist circumference

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

糖化血红蛋白

指标类型:

主要指标

Outcome:

Hemoglobin A1C

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 25 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

通过计算机产生随机数字来将研究对象随机分配到干预组和对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Subjects were assigned to the intervention or control groups by simple randomization on a 1:1 basis

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2015-01-29 20:17:56